Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of standard chemotherapy with or without INCB161734 in participants with metastatic pancreatic ductal adenocarcinoma (PDAC).
Sponsor: Incyte Corporation
NCT ID: NCT07522073
Sites in South Carolina: - Investigative Site US082 — Charleston, South Carolina
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the safety and efficacy of atebimetinib in combination with modified GnP compared with SOC GnP alone.
Sponsor: Immuneering Corporation
NCT ID: NCT07562152
Sites in South Carolina: - Prisma Health — Greenville, South Carolina
Phase 3 Recruiting Industry
The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting o…
Sponsor: Pierre Fabre Medicament
NCT ID: NCT03394365
Sites in South Carolina: - Medical University of South Carolina (Adults and Pediatrics) — Charleston, South Carolina
Phase 2 Recruiting Network
This phase II trial studies the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors. Chemotherapy drugs, such as capecitabine and temozolomide, work…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05040360
Sites in South Carolina: - Prisma Health Cancer Institute - Spartanburg — Boiling Springs, South Carolina
- Medical University of South Carolina — Charleston, South Carolina
- Prisma Health Cancer Institute - Easley — Easley, South Carolina
- Prisma Health Cancer Institute - Butternut — Greenville, South Carolina
- Prisma Health Cancer Institute - Faris — Greenville, South Carolina
Phase 2 Recruiting Academic/Other
This phase II study evaluates how well pemigatinib works for the treatment of adult patients with pancreatic cancer that has spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or has s…
Sponsor: Sameek Roychowdhury
NCT ID: NCT06906562
Sites in South Carolina: - Ohio State University-Telemedicine — Charleston, South Carolina
Phase 2 Recruiting Industry
This is a randomized, double-blind, placebo-controlled basket trial evaluating mifomelatide (TCMCB07) administered daily by subcutaneous (SC) injection in up to 120 patients. Patients will be enrolled into two cohorts 1) patients with newl…
Sponsor: Endevica Bio
NCT ID: NCT06937177
Sites in South Carolina: - Medical University of South Carolina — Charleston, South Carolina
Phase 1 Recruiting Industry
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity when ABBV-400 is given to adult participants to treat adva…
Sponsor: AbbVie
NCT ID: NCT06084481
Sites in South Carolina: - MUSC Hollings Cancer Center /ID# 257935 — Charleston, South Carolina
- Prisma Health /ID# 257697 — Greenville, South Carolina
Phase 1 Recruiting Industry
The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical data, this bifunctional antibody may exert synergistic activity in patients with EGFR-driv…
Sponsor: Bicara Therapeutics
NCT ID: NCT04429542
Sites in South Carolina: - Medical University of South Carolina, Hollings Cancer Center — Charleston, South Carolina
Phase 1 Recruiting Industry
This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-313 administered o…
Sponsor: MOMA Therapeutics
NCT ID: NCT06545942
Sites in South Carolina: - Investigative Site #107 — Myrtle Beach, South Carolina
Phase 1 Recruiting Industry
A phase 1a/1b, multicenter, open-label, dose escalation/expansion, multiple-dose study to evaluate the safety and activity of DR-0202 in patients with locally advanced or metastatic, relapsed or refractory carcinomas
Sponsor: Dren Bio
NCT ID: NCT06999187
Sites in South Carolina: - Dren Investigational Site — Greenville, South Carolina
Recruiting Network
The purpose of this study is to compare two approaches for monitoring pancreatic cysts as well as to identify associated biomarkers. The study doctors want to compare more frequent monitoring versus less frequent monitoring as well as iden…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT04239573
Sites in South Carolina: - Prisma Health Cancer Institute - Spartanburg — Boiling Springs, South Carolina
- Roper Hospital — Charleston, South Carolina
- Bon Secours Saint Francis Hospital — Charleston, South Carolina
- Prisma Health Cancer Institute - Laurens — Clinton, South Carolina
- Prisma Health Richland Hospital — Columbia, South Carolina
Recruiting Academic/Other
This study evaluates cancer-related weight and muscle mass loss, symptoms, and physical function (cachexia) in patients undergoing treatment for colorectal, lung, or pancreatic cancer that cannot be removed by surgery (unresectable) or is …
Sponsor: University of Rochester
NCT ID: NCT06073431
Sites in South Carolina: - AnMed Health Cancer Center — Anderson, South Carolina
- Saint Joseph's/Candler - Bluffton Campus — Bluffton, South Carolina
- Gibbs Cancer Center-Gaffney — Gaffney, South Carolina
- Prisma Health Cancer Institute - Butternut — Greenville, South Carolina
- Prisma Health Cancer Institute - Faris — Greenville, South Carolina
Recruiting Industry
The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinica…
Sponsor: Guardant Health, Inc.
NCT ID: NCT05059444
Sites in South Carolina: - Carolina Urologic Research Center — Myrtle Beach, South Carolina
- Carolina Blood and Cancer Care Associates — Rock Hill, South Carolina
Recruiting Industry
This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types. The cancers included in this study are brain, breast, …
Sponsor: Adela, Inc
NCT ID: NCT05366881
Sites in South Carolina: - Medical University of South Carolina — Charleston, South Carolina
- McLeod Health — Florence, South Carolina
Recruiting Academic/Other
The purpose of this study is to create a registry to provide insight into treatment selection and treatment outcome of pancreatic IRE in order to develop an evidence base such that physicians can provide the best possible care to patients …
Sponsor: University of Louisville
NCT ID: NCT02674100
Sites in South Carolina: - Gibbs Cancer Research, Spartanburg Regional Healthcare System — Spartanburg, South Carolina
Recruiting Academic/Other
This study aims to prospective validate an exosome-based miRNA signature for noninvasive and early detection of pancreatic ductal adenocarcinoma.
Sponsor: City of Hope Medical Center
NCT ID: NCT06388967
Sites in South Carolina: - Piedmont Medical Center — Rock Hill, South Carolina